Summit Therapeutics Share Discussion Threads

[waterloo01] 11/9/2019 07:43

Antibiotics given to 80% of premature babies may alter their gut bacteria for DECADES - and leave them more vulnerable to superbugs, study finds

[waterloo01] 09/9/2019 13:24

volume is the key IMO

[kirk 6] 09/9/2019 13:20

Nasdaq has had a pretty good run without any rise in UK so I think today's tiny rally is just a catch up to Nasdaq

[waterloo01] 09/9/2019 13:13

Nasdaq will be informative. If we get some volume it suggests we have some news incoming. (last time it was Barda news). Hard to keep grant type info from leaking as it's not kept 'in-house'

[kirk 6] 09/9/2019 13:10

About time wake me up when we are back to mid 30s

[waterloo01] 09/9/2019 13:06

Are we actually up today. Wonders never cease.

[kirk 6] 05/9/2019 18:43

Maybe one day with all the good news recently we will hopefully be back there in 17 months. Long time for some yes but I'm prepared to wait and haven't even traded this one

[guss] 05/9/2019 17:48

I thought that when it was £2.20

[kirk 6] 05/9/2019 12:06

More nice news out. This really has got blockbuster potential just a matter of waiting

[chrisatrdg] 04/9/2019 13:49

RNS Today

Summit Therapeutics plc
(‘Summit’; or the ‘Company’;)

Summit Therapeutics to Participate in Upcoming Investor Conferences

Oxford, UK, and Cambridge, MA, US, 4 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will participate in several upcoming investor conferences taking place in New York City.

9 September 2019 – Janney Healthcare Conference

10 September 2019 – H.C. Wainwright 21st Annual Global Investment Conference, presentation at 12:05pm EDT

23-24 September 2019 – Oppenheimer Fall Summit

A live webcast of the H.C. Wainwright presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. There will be no podium presentations at the Janney and Oppenheimer conferences.

[kirk 6] 03/9/2019 21:23

Up over 3% again on the Nasdaq time for a turn in uk tomorrow

[kirk 6] 30/8/2019 22:17

Something must be wrong with the ticker SMMT tonight it is not a red colour. ADVFN are
Currently shut so will log a complaint Monday

[waterloo01] 30/8/2019 16:39

And why SUM's approach in showing superiority and providing the economic case are part of the trial design.

[waterloo01] 30/8/2019 16:23

Chris, thanks interesting. The upcoming milestones leave 2020 rather empty. Hopefully this will be filled with the 1st phases in gonorrhoea.

Do like their positioning though.

[chrisatrdg] 30/8/2019 16:08

It maybe just me but I have not been able to find the presentation from the
Canaccord Genuity Growth Conference & so phoned Summit this afternoon it is a matter of clicking on the title per link below:

[waterloo01] 30/8/2019 07:53

NHS chief says that superbugs could kill us before climate change does
Dame Sally Davies warns 10million people could die every year from superbugs
England's chief medical officer says we are 'underinvesting in sorting it out'

[bermudashorts] 27/8/2019 17:02

Thanks Waterloo - link below. Worth a read as overall the tone is more positive/hopeful than many other articles on AMR.

[waterloo01] 27/8/2019 16:07

See we are quoted in FT today

'Glyn Edwards' "the future lies in antibiotics that kill a specific pathogen without harming other bacteria, such as Summit’s lead product ridinilazole which is in Phase 3 trials for treating C. difficile infection. “I doubt that anyone will find a new broad-spectrum antibiotic,” he says. “Narrow spectrum, combined with new diagnostic technology, is the place to be because it leaves the patient’s microbiome intact.”

Search FT for 'Biotechs fight fears of ‘antibiotic apocalypse’

[waterloo01] 27/8/2019 07:35

Not sure about slowing RDZ but agree would be excellent to see some movement on Gonorrhoea, maybe using the Limited population pathway.

[chrisatrdg] 27/8/2019 07:28

Hi waterloo01 thanks for the posting surely the penny will drop soon as to how important Summits pre clinical drug to combat Gonnorrhea is & that it would make a good investment.If I were Summit I would go for a funding on the basis of its Discuver drugs
which would get it through into next year & slowdown C-Diff.

[waterloo01] 26/8/2019 18:27

Gonorrhea diagnoses increased by 67% between 2013 and 2017, according to the CDC.

"We expect gonorrhea will eventually wear down our last highly effective antibiotic, and additional treatment options are urgently needed," said Gail Bolan, M.D., director of the CDC's Division of STD Prevention, when it released those figures.

[waterloo01] 21/8/2019 14:18

As posted on twitter by Summit.

Clinical Review State of the Art Review
Clostridioides difficile: diagnosis and treatments
BMJ 2019; 366 doi: hxxps://doi.org/10.1136/bmj.l4609 (Published 20 August 2019)
Cite this as: BMJ 2019;366:l4609

Emerging treatments
Ridinilazole
Ridinilazole is a novel antibiotic with a targeted activity on C difficile. A phase 1 study showed a positive safety profile, supporting its clinical development.163 A phase 2 trial compared ridinilazole with vancomycin in 100 patients, the primary endpoint being a sustained clinical response.164 Ridinilazole was found superior to vancomycin, the sustained clinical response reaching 66.7% in the treatment group compared with 42.4% in patients treated with vancomycin. Two phase 3 studies are due to start in 2019 (NCT03595553 and NCT03595566).

To summarise, five drugs are currently available to treat C difficile infection: metronidazole, vancomycin, fidaxomicin, tigecycline, and teicoplanin. A systematic review and network meta-analysis screened 23 004 studies and selected 24 trials including a total of 5361 patients and compared treatments for non-multiply recurrent infections with C difficile.176 For sustained clinical cure, fidaxomicin and teicoplanin were better than vancomycin. Vancomycin, fidaxomicin, teicoplanin, ridinilazole, and surotomycin were all better than metronidazole. A Cochrane analysis was consistent with those conclusions: in mild infections, vancomycin is superior to metronidazole and fidaxomicin to vancomycin.177

[chrisatrdg] 21/8/2019 11:21

Hi Hugus Maximus - Good to see you are 'with us' are you still holding but with a large loss as I am.

You missed a good AGM in London the conclusion from those of us that went believe we will have some funding news sometime soon particularly with monies running out end Jan 2020.

The next news front I expect may be sometime next month when I am expecting the half year results.Regards.

[waterloo01] 20/8/2019 16:32

I understand she's still working on it, just not anything to do with SUMM. Back to the lab.

[hugus maximus] 20/8/2019 12:56

Hello Waterloo ... and still Sarepate seem to have no further progress in more meaningful data? Just that trial with the 10 boys.

Whatever happened to Dame Kay and Ezutromid? I've just done a search online and can't find anything beyond the news of Summit disappointment mid 2018. Very sad ... having seen the ongoing Sarepta shenanigans the boys and families must be extremely anxious when they see this latest FDA note.